Business · 14/07/2026
FDA Releases Final Guidance on Topical Dermatologic Corticosteroids Bioequivalence
The US Food and Drug Administration (FDA) has released a final guidance for industry on demonstrating the bioequivalence of topical dermatologic corticosteroids, replacing a previous 1995 guidance and finalizing a 2022 draft.
Original source language: Federal Register — Health and Human ServicesOpen original release →